UMIN-CTR Clinical Trial

Basic information
Official scientific title of the study	Minimum effective dose of lactulose for intestinal function. exploratory study
Title of the study (Brief title)	Minimum effective dose of lactulose for intestinal function.
Region	Japan

Condition
Condition	Not applicable
Classification by specialty	Not applicable Adult
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	To research the minimum effective dose of lactulose for intestinal function.
Basic objectives2	Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	Feces frequency, Feces hardness
Key secondary outcomes	Intestinal bacteria number

Base
Study type	Interventional

Study design
Basic design	Single arm
Randomization	Non-randomized
Randomization unit
Blinding	Open -no one is blinded
Control	Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms	1
Purpose of intervention	Treatment
Type of intervention	Food
Interventions/Control_1	Intake of lactulose 1, 2, 3g/day for 2weeks sequentially
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	18 years-old <=
Age-upper limit	Not applicable
Gender	Male and Female
Key inclusion criteria	1) Subjects with feces frequency 2-4 times / week
Key exclusion criteria	1) Subjects with severe hepatic, renal, heart, gastrointestinal, cerebrovascular, endocrine, metabolic or infection diseases. 2) Subjects with the history of gastrointestinal resection. 3) Subjects with gastrointestinal dysfunction such as irritable bowel syndrome or inflammatory bowel disease. 4) Subjects who use medicines or supplements that may influence feces frequency; e.g. antibiotics, probiotics, laxatives, antidiarrheals, fibers. 5) Subjects with milk allergy. 6) Subjects who participate another study. 7) Subjects who are judged inappropriate for the study by the investigator or the physician.
Target sample size	30

Research contact person
Name of lead principal investigator	Hisakazu Iino
Organization	Showa Women's University
Division name	Graduate School, Science for Living System
Address	1-7-57 Taishidou Setagaya-ku Tokyo
TEL	03-3411-4828
Email	iino@swu.ac.jp

Public contact
Name of contact person	Hisakazu Iino
Organization	Showa Women's University
Division name	Graduate School, Science for Living System
Address	1-7-57 Taishidou Setagaya-ku Tokyo
TEL	03-3411-4828
Homepage URL
Email	iino@swu.ac.jp

Sponsor
Institute	Showa Women's University
Institute
Department

Funding Source
Organization	Morinaga Milk Industry Co., LTD.
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funｄer(s)

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2016 Year 03 Month 15 Day

Progress
Recruitment status	Completed
Date of protocol fixation	2015 Year 12 Month 16 Day
Anticipated trial start date	2016 Year 04 Month 01 Day
Last follow-up date	2016 Year 07 Month 29 Day
Date of closure to data entry	2017 Year 02 Month 21 Day
Date trial data considered complete	2017 Year 02 Month 27 Day
Date analysis concluded	2017 Year 04 Month 07 Day

Related information
URL releasing protocol
Publication of results	Unpublished
URL releasing results
Results
Other related information

Management information
Registered date	2016 Year 02 Month 26 Day
Last modified on	2017 Year 05 Month 11 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024473